Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (811)	4/5/1998 11:05:00 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 1029

This is part of a post I made on Yahoo, that may be of interest to some. It was a reply to a question about whether ribavirin could boost earnings $5 as one poster had stated. The Goldman Sachs report says: "...if at its peak, ribavirin garners the 400,000 - 500,000 patients, which is only 5% of the eligible market, it could add $4.00-$5.00 in EPS over time." speaking of ribavirin and the acquisition program, "...could conservatively accelerate EPS growth to 30% - 35%." "ICN trades at ... 45% discount to an accelerated 30% - 35% growth rate ..." "mid-cap pharmaceutical companies trade at an average 20% premium ratio of 1998 P/E to estimated three-year growth rate, suggesting further upside potential through multiple expansion." Not from GS, but we have the best marketing partner any business could ask for. The US government and it's minions are declaring war on Hep C. Ribavirin is their cruise missle. There will be substantial surprises on the upside as real earnings growth appears over the next several years. JMHO (except for the quotes from GS) Time will tell. ÿ